Tenderwize
Retour à la recherche

Open-House-Biologika-Rabattverträge 2026-03a - Eculizumab (exkl. der Indikation gMG und NMOSD)

Techniker Krankenkasse·Hamburg, Germany·Deadline Aug 30, 2027 · 369 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-03a - Eculizumab (exkl. der Indikation gMG und NMOSD)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

The notice explicitly states this is not a public procurement subject to competition law; legal recourse is via social...

Structured data indicates EU-funded (isEuFunded: true), but XML notice explicitly says no-eu-funds. This may affect rep...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Supply of Eculizumab (excluding indications gMG and NMOSD) under discount agreements with participating health insurance funds.
  • Agreement is open to all eligible pharmaceutical entrepreneurs; no exclusivity granted.
Afficher le résumé complet

The tender is an Open House procedure for the conclusion of discount agreements (Rabattverträge) under § 130a Abs. 8 SGB V for the active substance Eculizumab (excluding the indications gMG and NMOSD). It is not a public procurement subject to competition law but a voluntary framework. All eligible pharmaceutical entrepreneurs can join at any time during the contract term (max 17 months from 1 April 2026 to 31 August 2027). No estimated value is provided. The procedure is open, with no negotiation on terms. Submission is via email or post, not through the e-procurement portal. The notice is in German, performance in Germany.

Risques

The notice explicitly states this is not a public procurement subject to competition law; legal recourse is via social...

Structured data indicates EU-funded (isEuFunded: true), but XML notice explicitly says no-eu-funds. This may affect rep...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG for the offered medicinal products.
  • Must hold a valid marketing authorization for the medicinal product(s) or be otherwise entitled to place them on the market.

Administrative

  • Must submit a self-declaration regarding authorization and reliability (Anlage 4).

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2026-03a - Eculizumab (exkl. der Indikation gMG und NMOSD)

Conclusion of discount agreements for Eculizumab (excluding gMG and NMOSD) under an Open House procedure. All eligible pharmaceutical entrepreneurs can join at any time during the contract term.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Mar 2026 - Aug 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Aug 30, 2027

Détails de la procédure

Date de publication
24 Feb 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
132076-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3